Improving Functional Outcomes and Quality of Life in Patients With Rectal Cancer After Surgery With Intensified Follow-up & Surveillance

Recruiting Phase 3 Interventional Study
LARS - Low Anterior Resection Syndrome Rectal Cancer Surgery Rectal Cancer Quality of Life (QOL)
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Pivotal Trial This treatment is in the last trial phase before FDA approval. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Trial phase
Phase 3
Study type
Interventional
Purpose
Treatment
Participants needed
140 (estimated)
Sponsor
University Hospital, Basel, Switzerland · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
The goal of this clinical study is to gain further insights into the treatment of patients with Low Anterior Resection Syndrome (LARS) symptoms after rectal resection. The main question is: Can LARS symptoms and quality of life be improved by implementing an intensified follow-up program? Researchers will compare the results of the intervention group with the results of a control group in which pa…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * patients older than 18 years * patients with rectal cancer in the middle and lower third of the rectum in stages I to IV who underwent LAR with TME and protective ileostomy * able to give informed consent as documented by signature Exclusion Criteria: * dementia or other psy…
Contacts

Felicitas Wiedemann, Resident

+41 61 777 76 09

felicitasinga.wiedemann@clarunis.ch

CONTACT

Marco von Strauss und Torney, Senior physician

+41 61 777 7581

marco.vonstrauss@clarunis.ch

CONTACT